Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
OTCMKTS:MCUJF

Medicure Q2 2026 Earnings Results & Report

Medicure logo
$2.76 -0.04 (-1.43%)
As of 10/14/2026 03:58 PM Eastern

Medicure missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.10 versus the -$0.0474 consensus estimate, while revenue of $5.36 million topped the $2.45 million estimate by $2.91 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Medicure EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.0474
Beat/Miss
Missed by -$0.0526
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.36 million
Expected Revenue
$2.45 million
Beat/Miss
Beat by +$2.91 million
YoY Revenue Growth
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Q2 2026 Earnings FAQ

Medicure (OTCMKTS:MCUJF) reported earnings of -$0.10 per share for Q2 2026, missing the consensus estimate of -$0.0474. The report was announced on Friday, August 14, 2026.

Medicure reported revenue of $5.36 million for Q2 2026, against a consensus estimate of $2.45 million.

Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page.

Medicure Earnings Headlines

Medicure (OTCMKTS:MCUJF) Stock Crosses Above 50 Day Moving Average - What's Next?
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105044
MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS
October 1, 2026  |  marketscreener.comM
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
 |  The Oxford Club (Ad)
Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
September 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69697627-medicure-inc-medicure-announces-completion-of-enrollment-in-its-mend-pnpo-phase-3-clinical-trial-200.htm
Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
May 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q1-2026-210021888.html
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68566676-medicure-inc-medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call-200.htm
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings.

Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate.

Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.

View Medicure Profile
Earnings Tools